[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6390117A2 - Regimen de dosificación para un agonista de los receptores de s1p - Google Patents

Regimen de dosificación para un agonista de los receptores de s1p

Info

Publication number
CO6390117A2
CO6390117A2 CO11079290A CO11079290A CO6390117A2 CO 6390117 A2 CO6390117 A2 CO 6390117A2 CO 11079290 A CO11079290 A CO 11079290A CO 11079290 A CO11079290 A CO 11079290A CO 6390117 A2 CO6390117 A2 CO 6390117A2
Authority
CO
Colombia
Prior art keywords
dosage regime
agonist
receiver agonist
receiver
dosage
Prior art date
Application number
CO11079290A
Other languages
English (en)
Inventor
Robert Schmouder
Thomas Dumortier
Olivier David
Michael Looby
Original Assignee
Novartis Int Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6390117(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Int Pharm Ltd filed Critical Novartis Int Pharm Ltd
Publication of CO6390117A2 publication Critical patent/CO6390117A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composición Farmacéutica que comprenden un modulador o agonista de los receptores de S1P, de fórmula I,los cuales se administran siguiendo un régimen de dosificación en donde, durante los días iniciales del tratamiento, la dosificación diaria es más baja que la dosificación diaria convencional.
CO11079290A 2008-12-22 2011-06-23 Regimen de dosificación para un agonista de los receptores de s1p CO6390117A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13967208P 2008-12-22 2008-12-22
US21853009P 2009-06-19 2009-06-19
US24671509P 2009-09-29 2009-09-29

Publications (1)

Publication Number Publication Date
CO6390117A2 true CO6390117A2 (es) 2012-02-29

Family

ID=41667217

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11079290A CO6390117A2 (es) 2008-12-22 2011-06-23 Regimen de dosificación para un agonista de los receptores de s1p

Country Status (41)

Country Link
US (11) US20100160259A1 (es)
EP (7) EP3120844A1 (es)
JP (7) JP2012513401A (es)
KR (1) KR101347919B1 (es)
CN (1) CN102264359A (es)
AR (1) AR074826A1 (es)
AU (1) AU2009330176C9 (es)
BR (1) BRPI0923500A2 (es)
CA (1) CA2747802C (es)
CL (2) CL2011001529A1 (es)
CO (1) CO6390117A2 (es)
CR (1) CR20110274A (es)
CU (1) CU20110136A7 (es)
CY (4) CY1116990T1 (es)
DK (3) DK3453387T3 (es)
EA (1) EA201100978A1 (es)
EC (1) ECSP11011222A (es)
ES (3) ES2760607T3 (es)
FR (1) FR20C1060I1 (es)
HN (1) HN2011001759A (es)
HR (3) HRP20151190T1 (es)
HU (4) HUE048717T4 (es)
IL (3) IL213170A0 (es)
LT (3) LT3409274T (es)
LU (1) LUC00183I2 (es)
MA (1) MA32981B1 (es)
ME (2) ME03802B (es)
MX (2) MX2011006623A (es)
NO (1) NO2020038I1 (es)
NZ (1) NZ593065A (es)
PE (1) PE20120337A1 (es)
PL (3) PL2379067T3 (es)
PT (3) PT3453387T (es)
RS (2) RS59857B1 (es)
SG (1) SG171404A1 (es)
SI (3) SI3409274T1 (es)
TN (1) TN2011000272A1 (es)
TW (1) TW201028143A (es)
UY (1) UY32352A (es)
WO (1) WO2010075239A1 (es)
ZA (2) ZA201103863B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785484B2 (en) 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
MX2011006623A (es) 2008-12-22 2011-07-12 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p.
CN102548579A (zh) 2009-09-29 2012-07-04 诺瓦提斯公司 S1p受体调节剂的给药方案
US20110124605A1 (en) * 2009-11-20 2011-05-26 Shreeram Aradhye Use of an S1P Receptor Agonist
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
EA201201515A1 (ru) * 2010-05-06 2013-08-30 Новартис Аг Схема приема производных диарилсульфидов
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
FR2968556B1 (fr) 2010-12-13 2013-12-27 Centre Nat Rech Scient Inhibiteurs des infections a vih et leurs utilisations
EA026144B9 (ru) 2011-01-07 2021-10-26 Новартис Аг Твердофазная фармацевтическая композиция, содержащая гемифумаратную соль 1-{4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил}азетидин-3-карбоновой кислоты, и таблетка, ее содержащая
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
TW201320994A (zh) 2011-10-11 2013-06-01 Novartis Ag 投藥療程
CN104540800B (zh) 2012-08-17 2017-05-10 埃科特莱茵药品有限公司 制备(2z,5z)‑5‑(3‑氯‑4‑((r)‑2,3‑二羟基丙氧基)苯亚甲基)‑2‑(丙亚氨基)‑3‑(邻甲苯基)噻唑烷‑4‑酮的方法及在该方法中所用的中间产物
AU2014225534A1 (en) * 2013-03-06 2015-09-24 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
WO2015053878A1 (en) 2013-10-11 2015-04-16 Teikoku Pharma Usa, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
KR20160141841A (ko) * 2014-04-10 2016-12-09 노파르티스 아게 Ｓ１ｐ 조절제 즉시 방출 투여 요법
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
NZ771435A (en) * 2015-01-06 2024-08-30 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
JP2023501217A (ja) 2019-10-31 2023-01-18 イドーシア ファーマシューティカルズ リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
WO2021158848A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor agonist
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
CN113332435B (zh) * 2021-06-18 2022-10-18 广州中医药大学(广州中医药研究院) 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
EP1315735A4 (en) 2000-08-31 2005-04-06 Merck & Co Inc Phosphate derivatives as immunoregulatory compounds
ATE412408T1 (de) 2002-05-16 2008-11-15 Novartis Pharma Gmbh Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
JP4861177B2 (ja) * 2003-09-12 2012-01-25 ニューロノバ エービー 神経系の障害の処置
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
EP2359821A1 (en) * 2004-11-29 2011-08-24 Novartis AG Dosage regimen of an s1p receptor agonist
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1850689A4 (en) * 2005-02-10 2013-05-22 G I View Ltd TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT
DK2952177T3 (da) * 2007-10-12 2021-04-26 Novartis Ag Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
US8785484B2 (en) * 2008-03-17 2014-07-22 Actelion Pharmaceuticals Ltd Dosing regimen for a selective S1P1 receptor agonist
WO2009155475A1 (en) * 2008-06-20 2009-12-23 Novartis Ag Paediatric compositions for treating1 multiple sclerosis
BRPI0923213A2 (pt) * 2008-12-22 2016-01-26 Novaris Ag regime de dosagem de um agonista do receptor para s1p.
MX2011006623A (es) 2008-12-22 2011-07-12 Novartis Ag Regimen de dosificacion para un agonista de los receptores de s1p.

Also Published As

Publication number Publication date
LT3409274T (lt) 2020-02-10
US20220142949A1 (en) 2022-05-12
DK2379067T3 (en) 2015-12-07
US20200330407A1 (en) 2020-10-22
US20140148415A1 (en) 2014-05-29
ME03594B (me) 2020-07-20
DK3409274T3 (da) 2019-12-16
US20190091180A1 (en) 2019-03-28
CA2747802C (en) 2021-02-09
JP7329965B2 (ja) 2023-08-21
BRPI0923500A2 (pt) 2018-05-29
IL278914A (en) 2021-01-31
MA32981B1 (fr) 2012-01-02
ES2552823T3 (es) 2015-12-02
RS59857B1 (sr) 2020-02-28
ECSP11011222A (es) 2011-08-31
US20140066657A1 (en) 2014-03-06
CY2020036I2 (el) 2021-06-25
CR20110274A (es) 2011-07-19
SI3409274T1 (sl) 2020-03-31
PL2379067T3 (pl) 2016-02-29
HUE048717T2 (hu) 2020-08-28
CN102264359A (zh) 2011-11-30
EP3409274A1 (en) 2018-12-05
EA201100978A1 (ru) 2012-01-30
PE20120337A1 (es) 2012-04-24
EP4098256A1 (en) 2022-12-07
ZA201205942B (en) 2013-03-27
JP2017141238A (ja) 2017-08-17
SI2379067T1 (sl) 2016-01-29
WO2010075239A1 (en) 2010-07-01
PT3409274T (pt) 2019-12-17
FR20C1060I1 (fr) 2020-12-25
JP2019167360A (ja) 2019-10-03
MX2011006623A (es) 2011-07-12
PT2379067E (pt) 2015-12-23
ES2810823T3 (es) 2021-03-09
JP2012513401A (ja) 2012-06-14
HRP20201167T1 (hr) 2020-12-11
JP2024129030A (ja) 2024-09-26
HRP20151190T1 (hr) 2016-01-01
EP3677260A1 (en) 2020-07-08
NO2020038I1 (no) 2020-11-18
EP3120844A1 (en) 2017-01-25
AU2009330176C9 (en) 2017-01-05
KR101347919B1 (ko) 2014-01-07
AU2009330176C1 (en) 2016-12-08
US20160081949A1 (en) 2016-03-24
JP2014144970A (ja) 2014-08-14
PL3409274T3 (pl) 2020-06-01
RS60666B1 (sr) 2020-09-30
SG171404A1 (en) 2011-07-28
IL274756A (en) 2020-07-30
HUE048717T4 (hu) 2022-02-28
US20170189353A1 (en) 2017-07-06
LT3453387T (lt) 2020-08-25
PL3453387T3 (pl) 2020-11-02
AU2009330176A1 (en) 2011-07-07
US20160263061A1 (en) 2016-09-15
UY32352A (es) 2010-07-30
ZA201103863B (en) 2012-10-31
EP3409274B1 (en) 2019-11-20
CL2013001558A1 (es) 2013-10-25
LUC00183I2 (es) 2024-07-01
EP2379067A1 (en) 2011-10-26
ME03802B (me) 2021-04-20
KR20110096175A (ko) 2011-08-29
EP2379067B1 (en) 2015-09-02
JP2022103194A (ja) 2022-07-07
SI3453387T1 (sl) 2020-10-30
JP2016135752A (ja) 2016-07-28
MX2021010759A (es) 2022-07-19
US20100160259A1 (en) 2010-06-24
NZ593065A (en) 2012-11-30
AU2009330176B2 (en) 2014-03-06
PT3453387T (pt) 2020-08-11
HUE026869T2 (en) 2016-08-29
DK3453387T3 (da) 2020-08-10
TW201028143A (en) 2010-08-01
EP2907511A1 (en) 2015-08-19
CA2747802A1 (en) 2010-07-01
CY1122812T1 (el) 2021-05-05
US20110257133A1 (en) 2011-10-20
IL213170A0 (en) 2011-07-31
CY2020036I1 (el) 2021-03-12
LTPA2020005I1 (lt) 2020-12-10
HUE052048T2 (hu) 2021-04-28
CY1123255T1 (el) 2021-10-29
US20180289638A1 (en) 2018-10-11
CL2011001529A1 (es) 2012-02-24
HRP20192175T1 (hr) 2020-03-20
TN2011000272A1 (en) 2012-12-17
AR074826A1 (es) 2011-02-16
CU20110136A7 (es) 2012-01-31
EP3453387B1 (en) 2020-06-03
CY1116990T1 (el) 2017-04-05
HN2011001759A (es) 2013-11-26
ES2760607T3 (es) 2020-05-14
HUS2000046I1 (hu) 2020-12-28
EP3453387A1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
CO6390117A2 (es) Regimen de dosificación para un agonista de los receptores de s1p
UY32350A (es) Régimen de dosificación de un agonista de los receptores de s1p
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
SV2011004061A (es) Aril-piridinas como inhibidores de sintasa de aldosterona
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
PE20150887A1 (es) Compuestos de benceno sustituidos
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
UY33075A (es) Derivados de ciclohexano y usos de los mismos
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY32853A (es) Nuevos compuestos de oxadiazol
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CL2009002017A1 (es) Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
CO6400188A2 (es) Inhibidores de la fosfodiesterasa tipo iii (pdeiii) o agentes sensibilizantes al ca2+ para elt ratamiento de la cardiomiopatia hepertrófica
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
UY32360A (es) Compuestos de etanamina y métodos de utilización de los mismos 545
CU20130155A7 (es) Régimen de dosificación para un agonista de los receptores de s1p
CR11188A (es) Compuestos de bencensulfonamida apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
CY1115622T1 (el) Εστερες μετρονιδαζολης για αντιμετωπιση ροδοχρου ακμης
CO6680616A2 (es) Compuestos de tiofeno 2.3.5- trisustituidos y usos de los mismos
UY29256A1 (es) Uso de deirvados de acido ciclopropanoico sustituidos para producir medicamentos para tratar el síndrome metabólico

Legal Events

Date Code Title Description
FC Application refused